Biogen Inc. shared on Tuesday that its GAAP diluted earnings per share in the third quarter of fiscal 2022 amounted to $7.84, surging approximately 253% on a yearly basis.

Meanwhile, total revenue for the three months ending September 30 landed at $2.5 billion, decreasing from $2.8 billion recorded in the same time frame a year earlier. On the other hand, net income in the same period skyrocketed 244% to stand at $1.1 billion.

Biogen revised its full-year guidance, with total revenue now being predicted at between $10.0 billion and $10.15 billion. "In the third quarter, Biogen made important progress toward building a foundation for growth while executing against our core business objectives," CEO Michel Vounatsos noted.